Interleukin-6: A potential target for post-thrombotic syndrome

Annals of Vascular Surgery

Volumn 25, Issue 2, 2011, Pages 229-239

  Wojcik, Brandon M ^a   Wrobleski, Shirley K ^a   Hawley, Angela E ^a   Wakefield, Thomas W ^a   Myers Jr , Daniel D ^a,b   Diaz, Jose A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; IMMUNOGLOBULIN G; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; FIBROSIS; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INFERIOR CAVA VEIN; INFLAMMATORY CELL; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; THROMBOGENESIS; THROMBUS; VEIN WALL; VEIN WALL FIBROSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; CHEMOKINE CCL2; COLLAGEN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROSIS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MONOCYTES; POSTTHROMBOTIC SYNDROME; RNA, MESSENGER; TIME FACTORS; TUNICA INTIMA; UP-REGULATION; VENA CAVA, INFERIOR; VENOUS THROMBOSIS;

EID: 79951511305     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.avsg.2010.09.003     Document Type: Article

References (52)

1. N.F. Hopkins, and J.H. Wolfe ABC of vascular diseases. Deep venous insufficiency and occlusion BMJ 304 1992 107 110
2. J.S. Ackroyd, and N.L. Browse The investigation and surgery of the post-thrombotic syndrome J Cardiovasc Surg (Torino) 27 1986 5 16 (Pubitemid 16181059)
3. D. Negus The post-thrombotic syndrome Ann R Coll Surg Engl 47 1970 92 105
4. A.A. Ashrani, and J.A. Heit Incidence and cost burden of post-thrombotic syndrome J Thromb Thrombolysis 28 2009 465 476
5. P. Prandoni, A.W. Lensing, and A. Cogo The long-term clinical course of acute deep venous thrombosis Ann Intern Med 125 1996 1 7
6. T.W. Wakefield, R.M. Strieter, and R. Schaub Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulation therapy J Vasc Surg 31 2000 309 324 (Pubitemid 30100041)
7. E.M. Roumen-Klappe, M.C. Janssen, and J. Van Rossum Inflammation in deep vein thrombosis and the development of post-thrombotic syndrome: a prospective study J Thromb Haemost 7 2009 582 587
8. T.W. Wakefield, M.J. Linn, and P.K. Henke Neovascularization during venous thrombosis organization: a preliminary study J Vasc Surg 30 1999 885 892
9. P.K. Henke, M.R. Varma, and K.B. Deatrick Neutrophils modulate post-thrombotic vein wall remodeling but not thrombus neovascularization Thromb Haemost 95 2006 272 281
10. M.R. Varma, A.J. Varga, and B.S. Knipp Neutropenia impairs venous thrombosis resolution in the rat J Vasc Surg 38 2003 1090 1098 (Pubitemid 37409647)
11. E.M. Roumen-Klappe, M. den Heijer, and S.H. van Uum Inflammatory response in the acute phase of deep vein thrombosis J Vasc Surg 35 2002 701 706
12. H. Shbaklo, C.A. Holcroft, and S.R. Kahn Levels of inflammatory markers and the development of the post-thrombotic syndrome Thromb Haemost 101 2009 505 512
13. N. Takagi, M. Mihara, and Y. Moriya Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis Arthritis Rheum 41 1998 2117 2121 (Pubitemid 29009369)
14. E.H. Choy, D.A. Isenberg, and T. Garrood Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial Arthritis Rheum 46 2002 3143 3150 (Pubitemid 35453522)
15. N. Nishimoto, K. Yoshizaki, and K. Maeda Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study J Rheumatol 30 2003 1426 1435 (Pubitemid 36835435)
16. N. Nishimoto, K. Yoshizaki, and N. Miyasaka Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial Arthritis Rheum 50 2004 1761 1769 (Pubitemid 38725087)
17. N. Nishimoto, J. Hashimoto, and N. Miyasaka Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab Ann Rheum Dis 66 2007 1162 1167 (Pubitemid 47309731)
18. J.S. Smolen, A. Beaulieu, and A. Rubbert-Roth Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial Lancet 371 2008 987 997 (Pubitemid 351392039)
19. H. Ito, M. Takazoe, and Y. Fukuda A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease Gastroenterology 126 2004 989 996 discussion 947 (Pubitemid 38451170)
20. S. Matsumoto, T. Hara, and K. Mitsuyama Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model J Immunol 184 2010 1543 1551
21. Y. Li, C. de Haar, and M. Chen Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis Gut 59 2010 227 235
22. H. Cash, M. Relle, and J. Menke Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus J Rheumatol 37 2010 60 70
23. D. Myers Jr., D. Farris, and A. Hawley Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis J Surg Res 108 2002 212 221 (Pubitemid 36062701)
24. J.A. Diaz, A.J. Booth, and G. Lu Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection Am J Transplant 9 2009 1773 1783
25. E.A. Fox, and S.R. Kahn The relationship between inflammation and venous thrombosis. A systematic review of clinical studies Thromb Haemost 94 2005 362 365 (Pubitemid 41122491)
26. J.A. Diaz, A.E. Hawley, and C.M. Alvarado Thrombogenesis with continuous blood flow in the inferior vena cava. A novel mouse model Thromb Haemost 104 2010 366 375
27. V. Sood, C. Luke, and E. Miller Vein wall remodeling after deep vein thrombosis: differential effects of low molecular weight heparin and doxycycline Ann Vasc Surg 24 2010 233 241
28. M. Nosaka, Y. Ishida, A. Kimura, and T. Kondo Immunohistochemical detection of MMP-2 and MMP-9 in a stasis-induced deep vein thrombosis model and its application to thrombus age estimation Int J Legal Med 124 2010 439 444
29. F. Bouzeghrane, X. Zhang, G. Gevry, and J. Raymond Deep vein thrombosis resolution is impaired in diet-induced type 2 diabetic mice J Vasc Surg 48 2008 1575 1584
30. J. Zhou, L. May, and P. Liao Inferior vena cava ligation rapidly induces tissue factor expression and venous thrombosis in rats Arterioscler Thromb Vasc Biol 29 2009 863 869
31. N. Nakata, Y. Kira, Y. Yabunaka, and K. Takaoka Prevention of venous thrombosis by preoperative glycyrrhizin infusion in a rat model J Orthop Sci 13 2008 456 462
32. P.K. Henke, M.R. Varma, and D.K. Moaveni Fibrotic injury after experimental deep vein thrombosis is determined by the mechanism of thrombogenesis Thromb Haemost 98 2007 1045 1055 (Pubitemid 350091134)
33. J. Gauldie, C. Richards, and D. Harnish Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells Proc Natl Acad Sci U S A 84 1987 7251 7255
34. T. Andus, T. Geiger, and T. Hirano Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells FEBS Lett 221 1987 18 22 (Pubitemid 17124045)
35. M. Kopf, H. Baumann, and G. Freer Impaired immune and acute-phase responses in interleukin-6-deficient mice Nature 368 1994 339 342 (Pubitemid 24104268)
36. V. Marin, F.A. Montero-Julian, and S. Gres The IL-6-soluble IL-6Ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin J Immunol 167 2001 3435 3442 (Pubitemid 32852589)
37. M. Romano, M. Sironi, and C. Toniatti Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment Immunity 6 1997 315 325 (Pubitemid 27148598)
38. S.M. Hurst, T.S. Wilkinson, and R.M. McLoughlin Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation Immunity 14 2001 705 714 (Pubitemid 32592418)
39. M.R. Varma, D.M. Moaveni, and N.A. Dewyer Deep vein thrombosis resolution is not accelerated with increased neovascularization J Vasc Surg 40 2004 536 542 (Pubitemid 39165031)
40. J. Humphries, C.L. McGuinness, and A. Smith Monocyte chemotactic protein-1 (MCP-1) accelerates the organization and resolution of venous thrombi J Vasc Surg 30 1999 894 899
41. S.A. Jones, S. Horiuchi, and N. Topley The soluble interleukin 6 receptor: mechanisms of production and implications in disease FASEB J 15 2001 43 58 (Pubitemid 32061655)
42. C. Lutticken, U.M. Wegenka, and J. Yuan Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130 Science 263 1994 89 92 (Pubitemid 24076262)
43. N. Stahl, T.G. Boulton, and T. Farruggella Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components Science 263 1994 92 95 (Pubitemid 24076263)
44. H.M. Hermanns, S. Radtke, and C. Haan Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130 J Immunol 163 1999 6651 6658
45. N. Stahl, T.J. Farruggella, and T.G. Boulton Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors Science 267 1995 1349 1353
46. S. Negoro, H. Oh, and E. Tone Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction Circulation 103 2001 555 561 (Pubitemid 32116241)
47. S.H. Jee, H.C. Chiu, and T.F. Tsai The phosphotidyl inositol 3-kinase/Akt signal pathway is involved in interleukin-6-mediated Mcl-1 upregulation and anti-apoptosis activity in basal cell carcinoma cells J Invest Dermatol 119 2002 1121 1127 (Pubitemid 35430489)
48. P. Rameshwar, T.N. Denny, D. Stein, and P. Gascon Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta J Immunol 153 1994 2819 2830 (Pubitemid 24278151)
49. X.M. Tang, Q. Dou, and Y. Zhao The expression of transforming growth factor-beta s and TGF-beta receptor mRNA and protein and the effect of TGF-beta s on human myometrial smooth muscle cells in vitro Mol Hum Reprod 3 1997 233 240 (Pubitemid 127509480)
50. E.F. Rocnik, B.M. Chan, and J.G. Pickering Evidence for a role of collagen synthesis in arterial smooth muscle cell migration J Clin Invest 101 1998 1889 1898 (Pubitemid 28226108)
51. A. Sebba Tocilizumab: the first interleukin-6-receptor inhibitor Am J Health Syst Pharm 65 2008 1413 1418
52. M. Jougasaki, T. Ichiki, Y. Takenoshita, and M. Setoguchi Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells Br J Pharmacol 159 2010 1294 1303